MX2022011842A - Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos. - Google Patents
Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos.Info
- Publication number
- MX2022011842A MX2022011842A MX2022011842A MX2022011842A MX2022011842A MX 2022011842 A MX2022011842 A MX 2022011842A MX 2022011842 A MX2022011842 A MX 2022011842A MX 2022011842 A MX2022011842 A MX 2022011842A MX 2022011842 A MX2022011842 A MX 2022011842A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- fap
- imaging agents
- present
- uses related
- Prior art date
Links
- 239000012216 imaging agent Substances 0.000 title abstract 2
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 2
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract 2
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 3
- 210000002950 fibroblast Anatomy 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037828 epithelial carcinoma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 238000010837 poor prognosis Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 210000002536 stromal cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El estroma tumoral, que representa una gran parte de la masa tumoral, representa un blanco atractivo para el suministro de compuestos diagnósticos y terapéuticos. Aquí, la atención se centra especialmente en una subpoblación de células del estroma, conocidas como fibroblastos asociados con el cáncer, que están presentes en más del 90 % de los carcinomas epiteliales, incluido el cáncer de páncreas, colon y mama. Los fibroblastos asociados con el cáncer presentan una alta expresión de FAP, que no es detectable en el tejido normal adulto, pero se asocia con un mal pronóstico en pacientes con cáncer. La presente invención proporciona agentes radiofarmacéuticos y de formación de imágenes de molécula pequeña basados en un inhibidor específico de FAP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993874P | 2020-03-24 | 2020-03-24 | |
| PCT/US2021/023862 WO2021195198A1 (en) | 2020-03-24 | 2021-03-24 | Fap-targeted radiopharmaceuticals and imaging agents, and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011842A true MX2022011842A (es) | 2022-10-20 |
Family
ID=77890585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011842A MX2022011842A (es) | 2020-03-24 | 2021-03-24 | Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11707539B2 (es) |
| EP (1) | EP4126053A1 (es) |
| JP (1) | JP2023519247A (es) |
| KR (1) | KR20220158038A (es) |
| CN (1) | CN115697413A (es) |
| AU (1) | AU2021244541A1 (es) |
| BR (1) | BR112022019121A2 (es) |
| CA (1) | CA3171183A1 (es) |
| CL (1) | CL2022002603A1 (es) |
| CO (1) | CO2022014985A2 (es) |
| IL (1) | IL296658A (es) |
| MX (1) | MX2022011842A (es) |
| PE (1) | PE20230490A1 (es) |
| TW (1) | TW202202150A (es) |
| WO (1) | WO2021195198A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023519247A (ja) | 2020-03-24 | 2023-05-10 | トラスティーズ オブ タフツ カレッジ | Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| WO2023069711A1 (en) * | 2021-10-22 | 2023-04-27 | Trustees Of Tufts College | Fap-targeted neutron capture agents, and uses and formulations related thereto |
| CN114149489B (zh) * | 2021-11-18 | 2023-12-15 | 厦门大学 | 一种靶向tigit的放射性标记化合物及其制备方法和应用 |
| CN115838393B (zh) * | 2023-02-16 | 2023-05-05 | 烟台蓝纳成生物技术有限公司 | 用于fapi合成的中间体及其制备方法和应用 |
| CN116120290A (zh) * | 2023-03-01 | 2023-05-16 | 广东药科大学附属第一医院 | 一种靶向成纤维细胞激活蛋白的mr探针的制备方法 |
| CN118619941A (zh) * | 2023-03-03 | 2024-09-10 | 晶核生物医药科技(南京)有限公司 | 一种含氮杂环类化合物及其制备方法与用途 |
| CN116650679A (zh) * | 2023-04-14 | 2023-08-29 | 河北医科大学第四医院 | 一种靶向fgfr1的影像探针及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399869B2 (en) * | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| AU2006264305B2 (en) | 2005-07-05 | 2012-07-05 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
| RU2011116223A (ru) * | 2008-09-25 | 2012-10-27 | Моликьюлар Инсайт Фармасьютикалз, Инк. (Us) | Селективные ингибиторы сепразы |
| EP3102242A2 (en) | 2014-02-03 | 2016-12-14 | Philochem AG | Targeted drug conjugates |
| EP3555627B1 (en) * | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| AU2019360944B2 (en) | 2018-10-17 | 2022-09-29 | Purdue Research Foundation | Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis |
| JP2023519247A (ja) | 2020-03-24 | 2023-05-10 | トラスティーズ オブ タフツ カレッジ | Ｆａｐ標的化放射性医薬品およびイメージング剤、ならびにそれらに関連する使用 |
-
2021
- 2021-03-24 JP JP2022557768A patent/JP2023519247A/ja active Pending
- 2021-03-24 CN CN202180037504.9A patent/CN115697413A/zh active Pending
- 2021-03-24 KR KR1020227036805A patent/KR20220158038A/ko unknown
- 2021-03-24 AU AU2021244541A patent/AU2021244541A1/en active Pending
- 2021-03-24 MX MX2022011842A patent/MX2022011842A/es unknown
- 2021-03-24 TW TW110110644A patent/TW202202150A/zh unknown
- 2021-03-24 EP EP21775253.4A patent/EP4126053A1/en active Pending
- 2021-03-24 IL IL296658A patent/IL296658A/en unknown
- 2021-03-24 WO PCT/US2021/023862 patent/WO2021195198A1/en active Application Filing
- 2021-03-24 PE PE2022002065A patent/PE20230490A1/es unknown
- 2021-03-24 US US17/211,481 patent/US11707539B2/en active Active
- 2021-03-24 BR BR112022019121A patent/BR112022019121A2/pt unknown
- 2021-03-24 CA CA3171183A patent/CA3171183A1/en active Pending
-
2022
- 2022-09-23 CL CL2022002603A patent/CL2022002603A1/es unknown
- 2022-10-21 CO CONC2022/0014985A patent/CO2022014985A2/es unknown
- 2022-11-18 US US17/990,347 patent/US20230330275A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115697413A (zh) | 2023-02-03 |
| PE20230490A1 (es) | 2023-03-23 |
| CA3171183A1 (en) | 2021-09-30 |
| IL296658A (en) | 2022-11-01 |
| JP2023519247A (ja) | 2023-05-10 |
| KR20220158038A (ko) | 2022-11-29 |
| US11707539B2 (en) | 2023-07-25 |
| CL2022002603A1 (es) | 2023-05-26 |
| AU2021244541A1 (en) | 2022-10-13 |
| US20220370647A1 (en) | 2022-11-24 |
| TW202202150A (zh) | 2022-01-16 |
| CO2022014985A2 (es) | 2022-12-30 |
| US20230330275A1 (en) | 2023-10-19 |
| BR112022019121A2 (pt) | 2023-02-14 |
| EP4126053A1 (en) | 2023-02-08 |
| WO2021195198A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011842A (es) | Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos. | |
| MX2021005808A (es) | Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer. | |
| Noorolyai et al. | The relation between PI3K/AKT signalling pathway and cancer | |
| Abu Aboud et al. | Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging | |
| Mantoni et al. | Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling | |
| Epenetos et al. | Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy | |
| MX2022008456A (es) | Inhibidores de mek y usos terapeuticos de estos. | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| Cuppini et al. | Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan | |
| Bhummaphan et al. | Cancer stem cell–suppressing activity of chrysotoxine, a bibenzyl from Dendrobium pulchellum | |
| Yoshida et al. | Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer | |
| Rose et al. | Presentation, treatment, and prognosis of secondary melanoma within the orbit | |
| Xie et al. | Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor α-mediated mechanisms | |
| CN105358173A (zh) | 靶向癌症治疗的egfr-sglt1相互作用 | |
| Ali-Rahmani et al. | Anticancer effects of mesothelin-targeted immunotoxin therapy are regulated by tyrosine kinase DDR1 | |
| Xia et al. | Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA‑MB‑231 cells | |
| MX2021005662A (es) | Compuestos activadores del receptor de aril hidrocarburo (ahr) como agentes terapéuticos para el cáncer. | |
| WO2020176461A3 (en) | Methods and compositions for treating neuroendocrine prostate cancer | |
| Trafalis et al. | Discovery of steroidal lactam conjugates of POPAM-NH2 with potent anticancer activity | |
| Giglio et al. | Intersphinteric resection for rectal cancer: role in fecal continence and quality of life | |
| JP6368811B2 (ja) | 放射線感受性を調節するためのｈｅｒ３阻害剤 | |
| Chen et al. | Increased expression of SSEA-4 on TKI-resistant non–small cell lung cancer with EGFR-T790M mutation | |
| MX2021002882A (es) | Focalizacion de egln1 en el cancer. | |
| Atkinson et al. | Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D+ T) or placebo (Pbo) in the COMBI-AD trial | |
| WO2022271771A3 (en) | Therapeutic targeting of cadherin 11 in cancer |